Reshma Kewalramani
CEO and President
Vertex Pharmaceuticals Incorporated · VRTX
$21.1M
Reported total · FY2025 · SCT Total as filed
Source: DEF 14A filed April 2, 2026. Prior years are from that filing's three-year table.
Catalog as of September 15, 2026. Not a live market feed.
- Salary
- $1.6M
- Stock Awards
- $15M
- Incentives
- $4.1M
- Other
- $423K
Compensation History
| Fiscal Year | Salary | Stock Awards | Total Compensation |
|---|---|---|---|
| 2025 | $1,600,000 | $15,002,270 | $21,144,261 |
| 2024 | $1,541,154 | $15,002,202 | $21,538,668 |
| 2023 | $1,500,000 | $15,001,894 | $20,594,441 |
Current Position
- Title
- CEO and President
- Ticker
- VRTX · NASDAQ
- Fiscal Year
- 2025
SEC Sources
Fiscal years below are columns from the latest DEF 14A Summary Compensation Table (filed April 2, 2026), not separate historical filings.
| Fiscal Year | Source |
|---|---|
| 2025 | View SEC filing |
| 2024 | View SEC filing |
| 2023 | View SEC filing |
Accession 0000875320-26-000153.
Other Vertex Executives
Charles F. Wagner, Jr.
Evp & Chief Operating And Financial Officer
Vertex · VRTX
$8.2M
FY 2025 · DEF 14A
Carmen Bozic
EVP & Chief Medical Officer
Vertex · VRTX
$6.6M
FY 2025 · DEF 14A
Amit Sachdev
EVP & Chief Patient and External Affairs Officer
Vertex · VRTX
$6.8M
FY 2025 · DEF 14A
Nia Tatsis
EVP & Chief Regulatory and Quality Officer
Vertex · VRTX
$7M
FY 2025 · DEF 14A
Stuart A. Arbuckle
Former EVP & Chief Operating Officer
Vertex · VRTX
$10M
FY 2025 · DEF 14A